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ABSTRACT
The antitumorigenic activity of nonsteroidal anti-inflammatory
drugs (NSAIDs), cyclooxygenase (COX) inhibitors, is well estab-
lished, but responsible molecular mechanisms are not fully
understood. NSAIDs stimulate apoptosis by COX dependent
and independent mechanisms in colorectal cells in culture.
Identification of genes regulated by COX inhibitors could lead
to a better understanding of their proapoptotic and anti-neo-
plastic activities. Using subtractive hybridization, a cDNA which
was designated as NSAID activated gene (NAG-1) was identi-
fied from NSAID-treated HCT-116, human colorectal cells.
NAG-1 has an identical sequence with a novel member of the
TGF-b superfamily that has 5 different names. In the HCT-116
cells, NAG-1 expression is increased and apoptosis is induced
by treatment with some NSAIDs in a concentration and time-
dependent manner. NAG-1 transfected cells exhibited in-
creased basal apoptosis, increased response to NSAIDs and
reduced soft agar cloning efficiency. Furthermore, transplant-
able tumors derived from NAG-1 transfected HCT-116 cells
showed reduced tumorigenicity in athymic nude mice com-
pared with vector-transfected HCT-116 cells. The increased
NAG-1 expression by NSAIDs provides a suitable explanation
for COX-independent apoptotic effects of NSAIDs in cultured
cells. These data demonstrate that NAG-1 is an antitumorigenic
and proapoptotic protein, and its regulation by COX inhibitors
may provide new clues for explaining their proapoptotic and
antitumorigenic activities.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are po-
tent anti-inflammatory drugs and are also effective in reduc-
ing human and rodent colorectal cancer (Boolbol et al., 1996;
Taketo, 1998a,b). Epidemiological studies reveal a 40 to 50%
reduction in mortality from colorectal cancer resulting from
the use of NSAIDs (Thun et al., 1993). NSAIDs inhibit the
two isoforms of prostaglandin H synthase [cyclooxygenase
(COX)], COX-1 and COX-2, the enzymes responsible for the
formation of prostaglandins from arachidonic acid. COX-1 is
constitutively expressed, whereas mitogens, tumor pro-
motors, and growth factors regulate COX-2 expression
(Herschman, 1996). Some data link NSAID chemoprevention
in colorectal cancer cells to COX inhibition (Watson, 1998).
The expression of COX-2 seems to increase angiogenesis
(Tsujii et al., 1998) in tumors, and COX inhibitors can atten-
uate angiogenesis (Jones et al., 1999). The over-expression of
COX-2 in rat intestinal cells in culture attenuates butyrate-
induced apoptosis (Tsujii and DuBois, 1995), a response re-
versed by incubation with the COX inhibitor, sulindac sul-
fide. Although there is data demonstrating that the
antitumorigenic activity of NSAIDs is related to COX inhibi-
tion, other data suggest that NSAIDs have COX-independent
effects.
Human colorectal cells in culture have served as useful
models to examine the mechanisms by which COX expression
contributes to cancer development and to assess how COX
inhibitors reduce tumor development. COX inhibitors are
reported to enhance apoptosis, particularly in cultured cells
(Subbaramaiah et al., 1997), but many of these apoptotic
responses required a higher concentration than necessary for
COX inhibition (Hanif et al., 1996; Shiff et al., 1996; Piazza et
al., 1997). Higher concentrations are also required to in-
crease ceramide formation (Chan et al., 1998) and down-
regulate the transcriptional activity of the peroxisome prolif-
erator-activated receptor, PPARd (He et al., 1999). Thus, the
proapoptotic activity of COX inhibitors in cultured cells may
not only be dependent on inhibition of COX, but also inde-
pendent of COX inhibition.
One mechanism that has not been explored is that NSAIDs
The INDO29 sequences are deposited to GenBank with accession number
AF173860.
ABBREVIATIONS: NSAIDs, nonsteroidal antiinflammatory drugs; COX, cyclooxygenase; TGF-b, transforming growth factor-b; NAG-1, NSAID-
activated gene-1; DMSO, dimethyl sulfoxide; DFU, 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone; bp, base pair(s);
PI, propidium iodide; INDO, indomethacin; FACS, fluorescence-activated cell sorting; PCR, polymerase chain reaction.
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may stimulate apoptosis and other biological responses in
cell culture by altering gene expression. To test this hypoth-
esis, we looked for NSAID-inducible genes by suppression
subtractive hybridization (Diatchenko et al., 1996) using the
human colorectal adenocarcinoma cell line, HCT-116. Here,
we report that cyclooxygenase inhibitors stimulate apoptosis
and induce the expression of a novel member of the TGF-b
superfamily. We called this gene NSAID-activated gene
(NAG-1), but it has a sequence identical to that of five re-
cently reported genes (Bootcov et al., 1997; Lawton et al.,
1997). In this report, we present evidence for the regulation
of NAG-1 expression by COX inhibitors and demonstrate
that NAG-1 has antitumorigenic and proapoptotic activity.
Materials and Methods
Cell Line and Reagents. Cell lines in this study were purchased
from ATCC (Manassas, VA). Human colorectal carcinoma cells,
HCT-116, were maintained in McCoy’s 5A medium. Media were
supplemented with 10% fetal bovine serum and Gentamicin. Most
NSAIDs in this study were purchased from Sigma (St. Louis, MO)
and dissolved in DMSO, except sodium salicylate, which was dis-
solved in PBS. Sulindac sulfide and DFU (5,5-dimethyl-3-(3-fluoro-
phenyl)-4-(4-methylsulphonyl)phenyl-2 (5H)-furanone) were from
Merck, Celecoxib, and SC-58125 from Monsanto, NS-398 from Cay-
man. LM4101, LM4108, LM4115 were kindly provided by Dr. L.
Marnett (Vanderbilt University, TN).
Isolation of an Indomethacin (INDO)-Induced Gene from
HCT-116 Cells. Messenger RNAs were isolated from INDO-treated
(100 mM) or vehicle-treated (0.2% DMSO) HCT-116 cells using a poly
(A) spin mRNA isolation kit (New England BioLabs, MA). The cDNA
Subtraction kit was used to make the INDO (1) and INDO (2)
subtractive libraries according to the manufacturer’s protocol
(CLONTECH, Palo Alto, CA). A clone containing 159 bp was isolated
from the INDO-induced library and designated INDO29. This se-
quence was identical to sequences reported by five different groups
(Fig. 1A). The full-length cDNA containing the entire coding region
was isolated by reverse transcriptase-PCR using two primers from
PTGFB sequence (GenBank accession no. AF008393); sense strand,
59-ACCTGCACAGCCATGCCCGGGCA-39 and anti-sense strand, 59-
CAGTGGAAGGACCAGGACTGCTC-39.
Measurement of DNA Content and Apoptosis by FACS
Analysis. The DNA content for NSAIDs and vehicle treated HCT-
116 cells was determined by FACS. Cells were plated at 4 3 105
cells/well in six-well plates, incubated for 16 h, and then treated with
NSAIDs in the presence of serum. After treatment, the cells were
harvested, washed with PBS, fixed by the slow addition of cold 70%
ethanol to a total of 1 ml, and stored at 4°C overnight. The fixed cells
were pelleted, washed once with PBS, and stained in 1 ml of 20 mg/ml
propidium iodide (PI) and 1 mg/ml RNase in PBS for 20 min. Cells
(7500) were examined by flow cytometry using Becton Dickinson
FACSort equipped with CellQuest software by gating on an area-
versus-width dot plot to exclude cell debris and cell aggregates.
Apoptosis was measured by the level of subdiploid DNA contained in
cells after treatment with NSAIDs using CellQuest software. As a
second method of detecting apoptosis, TACS Annexin V-FITC kit
(Trevigen, Inc., Gaithersburg, MD) was used according to the man-
ufacturer’s protocol. Annexin V-positive/PI-positive and Annexin V-
positive/PI-negative cell populations were determined as apoptotic
populations from the total gated cells.
Northern and Western Blot Analyses. When reaching 60 to
80% confluence in 10-cm plates, the cells were treated at the indi-
cated concentrations and times with different NSAIDs in the absence
of serum. Total RNAs were isolated using TRIzol reagent (Life Tech-
nologies, Gaithersburg, MD) according to the manufacturer’s proto-
col. For Northern blot analysis, 10 mg of total RNA was denatured at
55°C for 15 min and separated in a 1.2% agarose gel containing 2.2
M formaldehyde, and transferred to Hybond-N membrane (Amer-
sham Pharmacia Biotech, Piscataway, NJ). After fixing the mem-
brane by UV, blots were prehybridized in hybridization solution
(Rapid-hyb buffer; Amersham) for 1 h at 65°C, followed by hybrid-
ization with cDNA labeled with [a-32P]dCTP by random primer
extension (DECAprimeII kit; Ambion, Austin, TX). The probes used
were either full-length NAG-1 or placental TGF-b clone (generously
provided by Dr. Bento-Soar, University of Iowa, Iowa City, IA). After
4 h incubation at 65°C, the blots were washed once with 23 SSC/
0.1% SDS at room temperature and twice with 0.13 SSC/0.1% SDS
at 65°C. Messenger RNA abundance was estimated by intensities of
the hybridization bands of autoradiographs using Scion Image (Scion
Corporation, Frederick, MD). Equivalent loading of RNA samples
was confirmed by hybridizing the same blot with a 32P-labeled b-ac-
tin probe that recognizes RNA of approximately 2 kilobase pairs.
The level of NAG-1 was evaluated using Western blot analysis
with anti-human-NAG-1 antibody. The antibody was generated in
this laboratory in rabbit from a specific peptide of the NAG-1 C-
terminus (KTDTGVSLQTYDDLLA). The antibody recognized both
the precursor and secreted forms of NAG-1. HCT-116 cells were
grown to 60 to 80% confluence in 10-cm plates and treated with
NSAIDs for 48 h in the absence of serum. The media were harvested
and concentrated approximately 15-fold using Centriprep 10 concen-
trators (Amicon Inc., Beverly, MA). Proteins (30 mg) were separated
by 15% SDS-polyacrylamide gel electrophoresis (PAGE) and trans-
ferred onto nitrocellulose membrane (Schleicher & Schuell, Keene,
NH). The blots were blocked for 1 h with 5% skim milk in Tris-
buffered saline/Tween 0.05%, and probed with anti-NAG-1 antibody
(1:5,000 in 1% skim milk in Tris-buffered saline/Tween 0.05%) at 4°C
overnight. After washing, the blots were treated with horseradish
peroxidase-conjugated secondary antibody for 1 h and washed sev-
eral times. The signal was detected by enhanced chemiluminescence
(Amersham Pharmacia Biotech) and autoradiography.
Soft Agar Cloning Assay. Soft agar assays were performed to
compare the clonogenic potential of HCT-116 cells in semisolid me-
dium. The stably transfected HCT-116 cells were resuspended at
3000 cells in 2 ml of 0.4% agar in McCoy’s 5A medium and plated on
top of 1 ml of 0.8% agar in six-well plates. Plates were incubated for
2 to 3 weeks at 37°C. Cell colonies were visualized by staining with
0.5 ml of p-iodonitrotetrazolium violet (Sigma).
Tumor Growth in Nude Mice. Thirty male nude mice (athymic
NCr-nu) were purchased from NCI/Taconic at 5 weeks of age and
were maintained in pathogen-free conditions. A total of 3 3 106 cells
in 0.1 ml of PBS were subcutaneously injected behind the anterior
forelimb bilaterally in each mouse. Growth curves for xenografts
were determined by externally measuring tumors in two dimensions.
Tumor measurement began when the size was more than 3 mm in
diameter (around 4 days after injection). Tumor volume was deter-
mined by the equation V 5 [(L 1 W) 0.5] 3 L 3 W 3 0.5236. Values
are the mean 6 S.E. of 18 xenografts per group.
Results
For these experiments, we chose the COX-deficient HCT-
116 cells (Sheng et al., 1997) and confirmed the lack of COX
expression and activity by Western and high-performance
liquid chromatography analyses, respectively (Hsi et al.,
2000). Despite the lack of COX expression, HCT-116 cells
undergo apoptosis during treatment with INDO, making this
cell line a useful tool to study COX-independent NSAID-
induced gene expression.
Identification of NSAIDs-Activated Gene. The sup-
pression subtractive hybridization method described by Di-
atchenko (1996) was used to determine whether NSAIDs
could stimulate gene expression. A clone, designated
INDO29, was isolated from the INDO-induced library. Char-
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acterization of this 159-bp fragment by sequence analysis
indicated that INDO29 is identical to the 39 region of a novel
TGF-b superfamily gene reported recently by five different
groups (Fig. 1A) (Bootcov et al., 1997; Hromas et al., 1997;
Lawton et al., 1997; Yokoyama-Kobayashi et al., 1997;
Paralkar et al., 1998). Although these genes are named dif-
ferently, sequence analyses revealed that the five genes are
almost identical, and belong to a new, uncharacterized
TGF-b superfamily. Specific PCR primers were used to gen-
erate a full-length clone from HCT-116 cells with sequence
identity to the genes shown in Fig. 1A. The full-length coding
region was obtained, was sequenced completely, and was
compared with the previously known five genes. We found
that 1 bp in the coding region is different among the six
genes, including our PCR product. Thus, the full-length
NAG-1 is essentially identical to the genes reported by five
other groups. Based on sequence homology, NAG-1 is a di-
vergent member of the TGF-b family genes, because the
seven-cysteine domain of NAG-1 shows 15 to 29% identity to
the other TGF-b superfamily members (data not shown).
Because this branch of the TGF-b superfamily has five dif-
ferent names, in this report, we designated this gene the
NSAID-activated gene, NAG-1.
Indomethacin Induces NAG-1 Expression and Apo-
ptosis. To confirm the increased expression of NAG-1 by
INDO, Northern and Western blot analyses were performed
on INDO-treated HCT-116 cells. The NAG-1 mRNA expres-
sion increased with time (Fig. 1B) with a marked increase in
expression observed at 24 and 48 h. NAG-1 protein levels
were also increased by INDO treatment dependent on the
duration of exposure. The increases in NAG-1 protein were
Fig. 1. Identification and expression of NAG-1. A, schematic diagram for reported genes named PLAB, PTGFB, PDF, MIC-1, and HP00269. The bar
indicates the coding region of cDNA with amino acids reported previously. Each clone is represented as follows: placenta bone morphogenic protein
(PLAB; GenBank accession number U88323) (Hromas et al., 1997); placenta TGF-b, (PTGFB; GenBank accession number AF008303) (Lawton et al.,
1997); prostate derived factor (PDF; GenBank accession number AF003934) (Paralkar et al., 1998); macrophage inhibitory cytokine-1 (MIC-1;
GenBank accession number AF019770) (Bootcov et al., 1997); novel TGF-b super family, HP00269 (GenBank accession number AB000584)
(Yokoyama-Kobayashi et al., 1997). The black bar labeled INDO29 indicates 159-bp fragment first identified by subtractive hybridization from
HCT-116 cells, whereas NAG-1 indicates the PCR-generated full-length cDNA. B, HCT-116 cells were treated with 100 mM INDO in the absence of
serum for various times. Left, Northern blotting was performed using the NAG-1 probe and reprobed with b-actin probe as indicated under Materials
and Methods. Levels of the 1.3-kb NAG-1 transcript were normalized to the levels of b-actin transcripts and are represented relative to 0 h treatment.
Right, for the Western analysis, HCT-116 cells were treated with 100 mM INDO for various times in the absence of serum. The media were harvested
and concentrated, and 30 mg of total protein was subjected to 15% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane,
and probed with anti-NAG-1 antibody. C, apoptosis and cell cycle kinetics of INDO-treated HCT-116 cells at different time points. HCT-116 cells were
treated with INDO, stained with PI, and analyzed by flow cytometry. Apoptosis is represented by the fold increase in the subG1 population over 0 h
treatment. D, concentration-dependent expression of NAG-1. HCT-116 cells were grown in varying concentrations of INDO for 24 h or 48 h, and
Northern (left) and Western analyses (right) were performed as described above. V indicates 0.2% DMSO. E, apoptosis and cell cycle kinetics of
INDO-treated HCT-116 cells at different concentrations. Apoptosis was analyzed by FACS using HCT-116 cells treated with different concentrations
of INDO for 48 h as described above.
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observed at 36 and 48 h and occurred at later time points
than the increases in mRNA.
It is known that NSAIDs induce apoptosis in cultured
colorectal cells, so flow cytometric analysis of the distribution
of cells at various stages of the cell cycle was performed. A
prolonged G1 phase and shortened S phase were observed
that were dependent on the duration of INDO treatment (Fig.
1C). The changes in the cell cycle are consistent with the
previous report that NSAIDs affect cell cycle progression in
colon cancer cells (Shiff et al., 1996). However, because G1
arrest occurs at an earlier time point than NAG-1 protein
expression, the cell cycle arrest and NAG-1 induction may be
independent events. Apoptotic cells were identified as the
subG1 population. The induction of apoptosis by INDO was
time-dependent, with nearly 3- and 4.5-fold increases ob-
served at 36 h and 60 h, respectively (Fig. 1C). These data
suggest a correlation between INDO-induced apoptosis and
INDO-induced NAG-1 protein expression, because similar
time courses were observed.
The induction of NAG-1 mRNA and protein by INDO were
also concentration-dependent (Fig. 1D). HCT-116 cells were
treated with concentrations of INDO ranging from 0 to 100
mM. Increases in both NAG-1 mRNA and protein were ob-
served at INDO concentrations as low as 10 mM, but were
maximum at 100 mM. Similarly, the induction of apoptosis
was dependent on the concentration of INDO, with a signif-
icant increase at 50 mM and a maximum at 100 mM (Fig. 1E).
A correlation was observed between the increases in
NAG-1 expression and the induction of apoptosis, but these
results did not address whether NAG-1 expression may be a
consequence of apoptosis. HCT-116 cells were treated with
sodium butyrate, a known apoptotic inducer. With this treat-
ment, apoptosis and/or G1 cell cycle arrest was observed, but
NAG-1 expression was not enhanced (data not shown). Thus,
the increased expression of NAG-1 is not the result of apo-
ptosis, cell cycle arrest, or cytotoxic effects, but is specific for
treatment with NSAIDs.
NSAIDs can also induce apoptosis in breast (Han et al.,
1998), lung (Castonguay et al., 1998), leukemia (Finstad et
al., 1998), and prostate (Palayoor et al., 1998) cell lines. Thus,
A549 lung epithelial cells, MCF-7 mammary cells, PC-3 pros-
tate cancer cells, and U937 leukemia cell lines were incu-
bated with INDO, and Northern blot analysis was performed.
NAG-1 gene expression and apoptosis was stimulated by
INDO treatment in the cell lines tested (data not shown).
These data show that the ability of NSAIDs to increase the
expression of NAG-1 is not restricted to colorectal carcinoma
cells.
Stimulation of NAG-1 Expression by Other NSAIDs.
To determine whether other NSAIDs increased apoptosis and
NAG-1 expression, conventional NSAIDs that inhibit both
COX-1 and COX-2, as well as selective COX-2 inhibitors were
examined. HCT-116 cells were treated with various NSAIDs
at the concentrations shown in Table 1 for 24 h, and Northern
analysis was performed using NAG-1 cDNA as a probe.
Treatment with different NSAIDs increased NAG-1 expres-
sion in a concentration-dependent manner. The conventional
NSAIDs increased NAG-1 gene expression by 2- to 5-fold,
whereas acetaminophen did not induce NAG-1 expression at
any concentration. Sulindac sulfide was the most effective at
increasing NAG-1 mRNA. The prodrug sulindac and its me-
tabolite sulindac sulfone, which are weak cyclooxygenase
inhibitors, did not induce NAG-1 expression. Interestingly,
COX-2 specific inhibitors did not increase NAG-1 expression,
with the exception of LM-4101 and SC-58125. The COX-2
inhibitor Celecoxib could not be fully tested because it was
toxic to these cells after 24-h incubation. The drugs LM-4101,
4108, and 4115 are derivatives of indomethacin and are
COX-2 specific inhibitors (Kalgutkar et al., 2000). In general,
a correlation was observed between the ability of various
NSAIDs to inhibit COX and to induce NAG-1, suggesting
that specific structural characteristics are necessary for
NAG-1 induction.
Because sulindac sulfide was the most potent inducer of
NAG-1 mRNA, NAG-1 protein expression was evaluated by
Western blot analysis (Fig. 2). At a concentration of 1 mM
sulindac sulfide, some increases in NAG-1 protein (1.5-fold)
were observed, and much greater increases in NAG-1 protein
were achieved at concentrations from 5 to 50 mM. Thus, an
excellent correlation exists between the sulindac sulfide con-
centrations required to enhance NAG-1 mRNA (Table 1) and
protein (Fig. 2).
NSAID stimulation of apoptosis was measured at the con-
centration yielding the highest fold increase in NAG-1
mRNA. As reported in Table 1, every NSAID that increased
NAG-1 expression also induced apoptosis, suggesting a cor-
relation between apoptosis and NAG-1 expression (r2 5 0.94).
The NSAID-induced apoptosis was confirmed by annexin V
assay, which can detect early apoptotic and late apoptotic/
necrotic cell populations (data not shown). These data con-
firmed the apoptosis data generated using the PI staining
method. The association between NSAID-induced apoptosis
and the increase in NAG-1 expression provides evidence that
NSAID-induced apoptosis may be mediated, in part, by the
NAG-1 expression.
NAG-1 Expression Enhances INDO-Induced Apopto-
sis. The correlations observed between the induction of
NAG-1 and of apoptosis necessitated construction of NAG-1
TABLE 1
NSAID-induced apoptosis and NAG-1 expression
Each NSAID was tested using at least three different concentrations to measure an
increase in NAG-1 mRNA. These data are representative of two independent exper-
iments. The concentration yielding maximal increase in NAG-1 mRNA was used for
apoptosis determination. The apoptosis data are reported as mean 6 S.D. by PI
staining methods (n 5 6).
Conventional NSAIDs Concentration NAG-1 mRNAinduction Apoptosis Ratio
mM Fold increase Fold induction
Sulindac 10–40 1.5 1.1 6 0.2
Sulindac sulfone 100–400 1.3 1.6 6 0.1
Sulindac sulfide 1–50 4.6 4.3 6 0.7
Indomethacin 10–100 2.2 2.9 6 0.1
Piroxicam 200–500 1.9 1.5 6 0.1
Diclofenac 50–200 3.7 4.0 6 0.3
Aspirin 1,000–10,000 3.5 3.5 6 0.5
Ibuprofen 100–500 2.0 1.9 6 0.4
Sodium salicylate 1,000–5,000 3.0 1.8 6 0.3
Acetaminophen 10–100 0.9 0.9 6 0.2
COX-2 specific inhibitors
NS-398 10–100 0.9 1.0 6 0.1
DFU 10–100 1.0 0.5 6 0.1
Celecoxiba 0.01–0.1 1.0 0.7 6 0.1
SC-58125 10–100 5.0 3.2 6 0.2
LM-4101 10–100 3.0 4.1 6 0.1
LM-4108 10–100 1.0 1.7 6 0.2
LM-4115 10–100 1.0 N.D.
a This compound was toxic to the HCT-116 cells at micromolar concentrations.
N.D., not determined.
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overexpressing cells to directly assess the biological activities
of NAG-1. HCT-116 cells were stably transfected with an
expression vector containing the full-length NAG-1 coding
region in the sense and antisense orientations. Despite re-
peated attempts, individual clones with high NAG-1 expres-
sion could not be isolated, because the clones did not survive
during expansion, possibly reflecting a high rate of apoptosis
(data not shown). Thus, a pooled population of cells obtained
after selection with G418 was used. These cells expressed
NAG-1 protein at 2.0-fold greater than the vector-transfected
cells. The anti-sense construct did not completely suppress
basal NAG-1 expression, because slightly lower NAG-1 levels
(0.7-fold) were observed compared with vector-transfected
cells (Fig. 3A). The sense-HCT-116 cells exhibited a slower
growth rate compared with vector-transfected cells or anti-
sense-HCT-116 cells (data not shown). A higher percentage of
the sense-HCT-116 cells underwent spontaneous apoptosis
compared with the vector-transfected HCT-116 cells, in
agreement with the higher level of NAG-1 expression (Fig.
3B). In contrast, the antisense-HCT-116 cells demonstrated
slightly lower spontaneous apoptosis, concomitant with
slightly lower basal expression of NAG-1 (Fig. 3B). These
stably transfected cells were incubated with INDO for 48 h
and percent apoptosis was determined by FACS analysis.
INDO enhanced NAG-1 expression and the percentage of
apoptotic cells by approximately 2-fold in the vector-HCT-116
cells, similar to results in Fig. 1C at 48 h in wild-type HCT-
116 cells. The NAG-1 expression in the sense cells increased
the apoptotic response to INDO, correlating with the in-
creased NAG-1 expression. In contrast, INDO did not in-
crease apoptosis or the expression of NAG-1 in antisense
HCT-116 cells (compare vehicle treated vector and antisense
to INDO treated vector and antisense in Fig. 3). These results
support the conclusion that the INDO induced expression of
NAG-1 is responsible, in part, for the INDO-induced apopto-
sis in HCT-116 cells.
NAG-1 Has Antitumorigenic Activity. The antitumori-
genic activity of NAG-1, independent of NSAIDs treatment,
was evaluated by determining whether NAG-1 expression
would affect cell growth in vitro and in vivo. Cloning effi-
ciency was examined by the soft agar cloning assay. The
ability to form colonies in soft agar is reflective of tumorige-
nicity. NAG-1 overexpression resulted in a dramatic reduc-
tion (;50%) of the clonogenic capacity of the cells (Fig. 4A).
The effect of NAG-1 on the growth of tumors was evaluated
as xenografts in nude mice. NAG-1 transfected (sense and
antisense) and vector-transfected HCT-116 cells were in-
jected subcutaneously into the flanks of athymic nude mice.
In comparison with the vector-transfected HCT-116 cells, the
antisense NAG-1 HCT-116 cells rapidly developed visible
tumors and exhibited dramatic growth throughout the time
course. The difference between the antisense and vector-
transfected cells was statistically significant (P 5 0.05). In
contrast, the sense NAG-1 HCT-116 cells grew at a slower
rate and the resulting tumors were smaller than those from
vector-transfected cells (P 5 0.02). The differences in growth
of tumors derived from the antisense NAG-1 cells and tumors
from sense NAG-1 cells were even more dramatic. After 25
days of growth, the tumors derived from the sense NAG-1
cells were approximately 35% the size of the antisense
NAG-1 cells. This difference between the tumors from sense
and antisense NAG-1 cells was highly statistically significant
(P 5 0.0002). Even with the rather modest changes in the
levels of NAG-1 in the transfected cells (Fig. 3A), profound
effects were observed in the growth of tumors derived from
these cells (Fig. 4B). Thus, data from in vitro and in vivo
Fig. 2. Western analysis of sulindac sulfide-treated HCT-116 cells. HCT-
116 cells were grown for 48 h in the presence of sulindac sulfide at the
indicated concentrations. The cell lysates were harvested in radioimmu-
noprecipitation assay buffer and Western analysis was performed as
described in Fig. 1. NAG-1 protein was expressed as a precursor form (35
kDa) in the cell lysates. The membrane was stripped and reprobed for
actin (Santa Cruz Biotechnology, Santa Cruz, CA) to evaluate equivalent
loading.
Fig. 3. Altered apoptosis in sense- and anti-sense- NAG-1 cells. A, West-
ern analysis of ectopic expression of NAG-1 in HCT-116 cells. The full-
length NAG-1 (sense strand and antisense strand) was cloned into
pCDNA3.1 expression vector and transfected into HCT-116 cells. Each
cell was grown under G418 (500 mg/ml) for 3 weeks and treated with
either vehicle or INDO (100 mM). After growing for 48 h, the media were
harvested, concentrated, and subjected to Western analysis. Total protein
(30 mg) was loaded in each lane, and the arrow indicates the NAG-1
protein band. B, the stably transfected HCT-116 cells (vector, sense, or
antisense NAG-1) were treated with vehicle or 100 mM INDO for 48 h.
The cells were harvested and apoptotic populations were examined using
PI staining as described in Fig. 1C. The data represent mean 6 S.D.
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studies support the hypothesis that NAG-1 has antitumori-
genic activity and that expression attenuates tumor develop-
ment.
Discussion
In this report, we present evidence that some NSAIDs
increase the expression of an uncharacterized and divergent
member of the TGF-b superfamily that we called NAG-1
(NSAIDs-activated gene). This protein possesses proapop-
totic and antitumorigenic activity. Incubation of the cells
with COX inhibitors at concentrations higher than required
to inhibit COX initiated apoptosis and increased expression
of NAG-1, suggesting a link between apoptosis and NAG-1
expression. Further evidence for this association between
NAG-1 expression and apoptosis was obtained using NAG-1
sense and antisense transfected HCT-116 cells. Overexpres-
sion of NAG-1 in sense-NAG-1 cells enhanced basal and
INDO-stimulated apoptosis, whereas the antisense-NAG-1
exhibited an attenuated response to INDO. Sense-NAG-1
HCT-116 colorectal cells display less clonogenic growth in
soft agar than control HCT-116 cells. The reduction of colony
growth in soft agar suggests that NAG-1 expression resulted
in apoptosis and/or cell growth arrest independent of NSAID
treatment. Furthermore, the growth rate in nude mice of
transplantable tumors derived from HCT-116 cells was at-
tenuated by NAG-1 expression, providing evidence for the
antitumorigenic activity of NAG-1. Our investigation was
focused on colorectal cells because the antitumorigenic effect
of NSAIDs is well documented for human colorectal cancer.
However, the increased expression of NAG-1 in response to
some NSAIDs was also observed in human breast, prostate,
and leukemia cell lines, suggesting that the increased NAG-1
expression is not restricted to colorectal tissue. The results
provide evidence supporting the following hypotheses: 1)
NAG-1 has antitumorigenic and proapoptotic properties; 2)
some NSAIDs regulate the expression of NAG-1; and 3) the
proapoptotic effects reported for COX inhibitors in cell cul-
ture are mediated, in part, by NAG-1 expression.
During preparation of this article, two reports were pub-
lished that presented evidence for the proapoptotic activity of
NAG-1. In addition, they report that NAG-1 (called PTGF-b
in these studies) is regulated by p53 tumor suppressor gene
(Li et al., 2000; Tan et al., 2000). NAG-1 was identified by
DNA chip technology as a target for p53 and two putative p53
binding sites were identified in the promoter of this gene.
Evidence was presented suggesting that PTGF-b (NAG-1)
could mediate the p53-dependent growth suppression. Ade-
novirus-mediated PTGF-b (NAG-1) expression in MCF-7,
breast cancer cells resulted in growth arrest and the induc-
tion of apoptosis (Li et al., 2000), a finding that is in agree-
ment with the results reported here for colorectal cells. Be-
cause HCT-116 cells express wild-type p53, one question is if
the NSAID-induced NAG-1 expression is mediated by the
p53 sites in the promoter. However, NSAID-induced NAG-1
expression was observed in p53-null, U937, and PC-3 cells
(Herrmann et al., 1998; Akashi et al., 1999). The biochemical
pathway for NSAID-induced apoptosis seems to not require
p53 induction (Piazza et al., 1997). Thus, NSAID and p53
regulation of NAG-1 expression may occur via independent
mechanisms.
Although most of these studies were done in HCT-116 cells
that are devoid of COX activity, interestingly, the NSAIDs
that stimulate the expression of NAG-1 are also character-
ized as potent inhibitors of COX enzymes. For example, the
COX inhibitor, sulindac sulfide, up-regulates NAG-1 expres-
sion, but the prodrug sulindac and the inactive metabolite
sulindac sulfone do not stimulate expression of this protein.
Furthermore, most COX-2 specific inhibitors were not effec-
tive at increasing NAG-1 expression in HCT-116 cells. How-
ever, one COX-2 specific inhibitor, SC-58125, was one of the
most effective stimulators of NAG-1 expression. The potency
for NAG-1 induction is sulindac sulfide . diclofenac . indo-
methacin . ibuprofen > sodium salicylate > aspirin > pi-
roxicam. The order potency for enhanced NAG-1 expression
is poorly correlated with the rank order of the inhibition of
COX. This suggests that the structural characteristics re-
sponsible for induction of NAG-1 are similar to, but distinct
Fig. 4. Antitumorigenic activity of NAG-1. A, soft agar assay using
NAG-1 overexpressing cells. Cells were grown in 0.4% soft agar for 2
weeks, and stained with p-iodonitrotetrazolium violet solution. The re-
sults are representative of three different experiments. The data repre-
sent mean 6 S.D. B, exponentially growing vector and NAG-1-transfected
HCT-116 cells (3 3 106 cells) were inoculated subcutaneously in athymic
nude mice. Tumors were measured externally on the indicated days in
two dimensions using calipers. Values are the mean 6 S.E. of n 5 18
xenografts. The statistical difference between the tumor volumes at the
final data point was determined by paired t test (antisense versus sense,
P 5 0.0002; vector versus sense, P 5 0.02; vector versus antisense, P 5
0.05). Vector represents vector-transfected HCT-116 cells, whereas sense
represents NAG-1-transfected and antisense represents antisense NAG-1
transfected HCT-116 cells. The data are representative of two indepen-
dent experiments.
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from the structural requirements responsible for inhibition of
COX. Interestingly, the most potent NAG-1 inducer is sulin-
dac sulfide, which has potent antitumorigenic activity and is
fairly effective in the treatment of familial adenoma polypo-
sis patients. The concentration of sulindac sulfide required to
enhance NAG-1 expression (5–10 mM) was similar to the
peak plasma concentration observed in human patients
(Kwan and Duggan, 1977). The plasma concentration of
INDO in patients is also approximately 5 mM. This concen-
tration is lower than the concentrations required increase
NAG-1 expression in cultured cells. Thus, additional evi-
dence is required to determine whether NAG-1 expression is
increased in patients receiving usual doses of NSAIDs and if
NAG-1 expression plays an important role in reduction of
colorectal cancer in humans and in experimental animals.
NAG-1 is a newly identified member of the TGF-b super-
family, but only shares 25% sequence identity with other
family members. However, it does contain the characteristic
consensus RXXRA/S cleavage signal for processing the im-
mature pro-form to the active secreted protein. Members of
the TGF-b family exert a wide range of activities regulating
cell growth, differentiation, matrix formation, and apoptosis.
The biological activity is not fully characterized. NAG-1
seems to induce cartilage and bone formation (Lawton et al.,
1997; Paralkar et al., 1998) and may suppress inflammation
by inhibiting macrophage activation (Bootcov et al., 1997).
TGF-b is recognized as an important negative regulator of
growth of colonic epithelial cells. Multiple lines of evidence
suggest that the TGF-b pathway is a potent tumor suppres-
sor of human colorectal cancer. Ectopic expression of NAG-1
in HCT-116 cells showed reduction in the growth rate of
transplantable tumors in nude mice, suggesting that NAG-1,
like other TGF-b proteins, has antitumorigenic activity.
Thus, NAG-1 inhibits cell growth and suppresses inflamma-
tion. Its regulation by COX inhibitors reveals a potentially
important mechanism to influence these biological processes.
The regulation of NAG-1 is not clearly understood and ex-
tensive promoter analysis is required to delineate the mech-
anisms by which NSAIDs induce NAG-1 expression. The
structural and chemical characteristics of NSAIDs responsi-
ble for COX inhibition may be similar to, but distinct from
the structural characteristics responsible for the up-regula-
tion of this member of the TGF-b superfamily. Once better
understood it should be possible to develop new antitumori-
genic and anti-inflammatory drugs that are potent stimula-
tors of NAG-1 expression but are not COX inhibitors and,
thus, devoid of the undesirable side effects of NSAIDs.
In summary, evidence is presented that NAG-1, a novel
member of the TGF-b superfamily, has proapoptotic and
antitumorigenic activities. NAG-1 expression is regulated by
some NSAIDs and therefore, the proapoptotic activity of
NSAIDs observed in cell culture systems seems to be linked
to the expression of NAG-1. The identification of NAG-1 as an
antitumorigenic gene regulated by NSAIDs may result in the
development of new drugs used in the treatment of human
cancers.
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